Molecules from animals with exotic immune systems can be big business, as Andrew Joseph from STAT News points out. Pharmaceutical giant Sanofi recently bought a company focused on nanobodies, originally derived from camels, llamas and alpacas, for $4.8 billion.
Lampreys’ variable lymphocyte receptors (VLRs) are their version of antibodies, even though they look quite different in molecular terms. Research on VLRs and their origins may seem impractical. However, Cooper’s team has shown their utility as diagnostic tools, and his colleagues have been weaponizing them, possibly for use in cancer immunotherapy.
CAR-T cells have attracted attention for dramatic elimination of certain types of leukemias from the body and also for harsh side effects and staggering costs; see this opinion piece by Georgia Tech’s Aaron Levine. Now many research teams are scheming about how to apply the approach to other types of cancers. The provocative idea is: replace the standard CAR (chimeric antigen receptor) warhead with a lamprey VLR.
Trent Spencer and colleagues recently published an update on this line of research. Although they found that a standard CAR anticancer weapon was superior to a VLR-based one when targeting one particular molecule on T cells, the paper’s conclusion says that VLRs could still be harnessed for targeting more generally:
“We cannot conclude that other VLRs would not provide adequate target cell killing, as our in vitro studies certainly show VLR sequences can efficiently activate T cells. There may be particular circumstances in which a VLR may be advantageous…”